A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

EP: 1.Cardiovascular Disease Risk in Men with Prostate Cancer

EP: 2.Examining the Data From Key Clinical Trials, and Practical Strategies

EP: 3.Strategies for Mitigating Cardiovascular Risk

EP: 4.Summary and Case Study

EP: 5.A Medical Oncologist Reflects on a Typical Prostate Cancer Patient

EP: 6.A Urologist Reflects on a Typical Prostate Cancer Patient

EP: 7.A Cardiologist Reflects on a Typical Prostate Cancer Patient

EP: 8.Practice-Related And Provider-Patient Communication Strategies For Prostate Cancer Care

EP: 9.A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 10.A Medical Oncologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 11.Typical Examinations And Tests For Cardiovascular Risk Assessment in a Cardiology Practice

EP: 12.Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice

EP: 13.A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation

EP: 14.A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation

EP: 15.Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

EP: 16.Considerations For ADT Selection And Patient Education on Treatment-Related AEs

EP: 17.A Urologist’s Approach to Followup For Patients on ADT And Practice Communication Strategies

Now Viewing

EP: 18.A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

EP: 19.A Urologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

EP: 20.A Cardiologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

January 2023 AbbVie Inc. Company Confidential

Related Videos

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.